State medicaid programs did not make use of prior authorization to promote safer prescribing after rosiglitazone warning

Health Affairs

Volumn 31, Issue 1, 2012, Pages 188-198

  Ross, Joseph S ^a   Jackevicius, Cynthia ^b   Krumholz, Harlan M ^a   Ridgeway, Jennifer ^c   Montori, Victor M ^c   Alexander, G Caleb ^d   Zerzan, Judy ^e   Fan, Jiaquan ^c   Shah, Nilay D ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e Colorado Department of Health Care Policy and Financing ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA;

ARTICLE; DIABETES MELLITUS; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HUMAN; INSURANCE; MEDICAID; PRESCRIPTION; PRESCRIPTIVE AUTHORITY; SAFETY;

GATEKEEPING; HUMANS; HYPOGLYCEMIC AGENTS; MEDICAID; PRESCRIPTIONS; STATE GOVERNMENT; THIAZOLIDINEDIONES; UNITED STATES;

EID: 84855702842     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2011.1068     Document Type: Article

References (26)

1. Medicaid.gov. Medicaid and CHIP provide health coverage to nearly million Americans [Internet]. Baltimore (MD): Centers for Medicare and Medicaid Services; [cited 2011 Dec 13]. Available from: https://www.cms.gov/MedicaidGenInfo
2. Smith V, Gifford K, Ellis E, Rudowitz R, O'Malley M, Marks C. Headed for a crunch: an update on Medicaid spending, coverage, and policy heading into an economic downturn: results from a 50-state Medicaid budget survey for state fiscal years 2008 and 2009 [Internet]. Washington (DC): Kaiser Commission on Medicaid and the Uninsured; 2008 Sep [cited 2011 Dec 13]. Available from: http://www.kff.org/medicaid/upload/7815.pdf
3. Fischer MA, Choudhry NK, Winkelmayer WC. Impact of Medicaid prior authorization on angiotensin-receptor blockers: can policy promote rational prescribing? Health Aff (Millwood). 2007; 26(3):800-7.
4. Fischer MA, Schneeweiss S, Avorn J, Solomon DH. Medicaid priorauthorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med. 2004;351(21):2187-94.
5. Virabhak S, Shinogle JA. Physicians' prescribing responses to a restricted formulary: the impact of Medicaid preferred drug lists in Illinois and Louisiana. Am J Manag Care. 2005;11 Spec No: SP14-20.
6. Soumerai SB. Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Aff (Millwood). 2004;23(1):135-46.
7. Polinski JM, Wang PS, Fischer MA. Medicaid's prior authorization program and access to atypical antipsychotic medications. Health Aff (Millwood). 2007;26(3):750-60.
8. Shah ND, Montori VM, Krumholz HM, Tu K, Alexander GC, Jackevicius CA. Responding to an FDA warning-geographic variation in the use of rosiglitazone. N Engl J Med. 2011;363(22):2081-4.
9. Lipska KJ, Ross JS. Switching from rosiglitazone: thinking outside the class. JAMA. 2011;305(8):820-1.
10. Montori VM, Shah ND. What have we learnt from the rosiglitazone saga? BMJ 2011;342:d1354.
11. Food and Drug Administration. Information for healthcare professionals: pioglitazone HCl (marketed as Actos, Actoplus Met, and Duetact) [Internet]. Silver Spring (MD): FDA; [last updated 2009 Nov 12; cited 2011 Dec 13]. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124178.htm
12. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-71.
13. Food and Drug Administration [Internet]. Silver Spring (MD): FDA. Press release, FDA issues safety alert on Avandia; 2007 May 21 [cited 2011 Dec 13]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108917.htm.
14. Food and Drug Administration. FDA Drug Safety Communication: Avandia (rosiglitazone) labels now contain updated information about cardiovascular risks and use in certain patients [Internet]. Silver Spring (MD): FDA; 2011 Feb 3 [cited 2011 Dec 13]. Available from: http:// www.fda.gov/Drugs/DrugSafety/ ucm241411.htm
15. Food and Drug Administration. Avandia (rosiglitazone): REMS-risk of cardiovascular events includes Avandia, Avandamet, and Avandaryl [Internet]. Silver Spring (MD): FDA; [last updated 2011 Nov 4; cited 2011 Dec 13]. Available from: http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ ucm226994.htm
16. Cohen A, Rabbani A, Shah N, Alexander GC. Changes in glitazone use among office-based physicians in the U.S., 2003-2009. Diabetes Care. 2010;33(4):823-5.
17. George J, Hannah S 5th, Lang CC. Thiazolidinediones and the influence of media adverse reporting on prescribing attitudes in practice (TZD-IMPACT) study. Cardiovasc Ther. 2009;27(2):83-8.
18. Morrow RL, Carney G, Wright JM, Bassett K, Sutherland J, Dormuth CR. Impact of rosiglitazone metaanalysis on use of glucose-lowering medications. Open Med. 2010;4(1): e50-9.
19. Starner CI, Schafer JA, Heaton AH, Gleason PP. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events. J Manag Care Pharm. 2008;14(6): 523-31.
20. Cohen M (Urban Institute; Washington, DC). An overview of Medicaid enrollees with diabetes in 2003 [Internet]. Washington (DC): Kaiser Commission on Medicaid and the Uninsured; 2007 Oct [cited 2011 Dec 22]. (Issue Paper). Available from: http://www.kff.org/medicaid/upload/7700.pdf
21. Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154(9):602-13.
22. Belongia EA, Sullivan BJ, Chyou PH, Madagame E, Reed KD, Schwartz B. A community intervention trial to promote judicious antibiotic use and reduce penicillin-resistant Streptococcus pneumoniae carriage in children. Pediatrics. 2001;108(3): 575-83.
23. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002; 27(4):299-309.
24. Durbin J, Watson GS. Testing for serial correlation in least squares regression, I. Biometrika. 1950;37: 409-28.
25. Durbin J, Watson GS. Testing for serial correlation in least squares regression, II. Biometrika. 1951;38: 159-79.
26. To access the Appendix, click on the Appendix link in the box to the right of the article online.